Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and michael acceptor group for maximal potency

Journal of Medicinal Chemistry

Volumn 53, Issue 20, 2010, Pages 7316-7326

  Wu, Chia Hsien ^a,c   Coumar, Mohane Selvaraj ^a   Chu, Chang Ying ^a   Lin, Wen Hsing ^a   Chen, Yi Rong ^b   Chen, Chiung Tong ^a   Shiao, Hui Yi ^a   Rafi, Shaik ^a   Wang, Sing Yi ^a   Hsu, Hui ^a   Chen, Chun Hwa ^a   Chang, Chun Yu ^a   Chang, Teng Yuan ^a   Lien, Tzu Wen ^a   Fang, Ming Yu ^a   Yeh, Kai Chia ^a   Chen, Ching Ping ^a   Yeh, Teng Kuang ^a   Hsieh, Su Huei ^a   Hsu, John T A ^a   Liao, Chun Chen ^a,d   Chao, Yu Sheng ^a,e   Hsieh, Hsing Pang ^a   more..

^a Division of Biotechnology and Pharmaceutical Research   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^e CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (2 HYDROXY 1 PHENYLETHYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 4 (4 METHYLPIPERAZINO) 2 BUTEN 1 ONE; 1 [4 (2 HYDROXY 1 PHENYLETHYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 4 MORPHOLINO 2 BUTEN 1 ONE; 1 [4 [(2 HYDROXY 1 PHENYLETHYL)AMINO] 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 2 PROPEN 1 ONE; 4 (DIETHYLAMINO) 1 [4 [(2 HYDROXY 1 PHENYLETHYL) AMINO] 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL) 2 BUTEN 1 ONE; 4 (DIMETHYLAMINO) 1 [4 (1 PHENYLETHYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL) 2 BUTEN 1 ONE; 4 (DIMETHYLAMINO) 1 [4 (1 PHENYLETHYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 2 BUTEN 1 ONE; 4 (DIMETHYLAMINO) 1 [4 (1 PHENYLPROPYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 2 BUTEN 1 ONE; 4 (DIMETHYLAMINO) 1 [4 (2 HYDROXY 1 PHENYLETHYL)AMINO 5,6,7,8 TETRAHYDROPYRIDO[4',3':4,5]THIENO[2,3 D]PYRIMIDIN 7 YL] 2 BUTEN 1 ONE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PELITINIB; TETRAHYDROPYRIDOTHIENO[2,3 D]PYRIMIDINE; UNCLASSIFIED DRUG; 1-(4-((2-HYDROXY-1-PHENYLETHYL)AMINO)-5,6,7,8-TETRAHYDROPYRIDO(4',3'-4,5)THIENO(2,3-D)PYRIMIDIN-7-YL)-2-PROPEN-1-ONE; 4-(DIMETHYLAMINO)-1-(4-(2-HYDROXY-1-PHENYLETHYL)AMINO-5,6,7,8-TETRAHYDROPYRIDO(4',3'-4,5)THIENO(2,3-D)PYRIMIDIN-7-YL)-2-BUTEN-1-ONE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FUSED HETEROCYCLIC RINGS; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CHIRALITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MALE; MOUSE; MUTANT; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MUTATION; NON SMALL CELL LUNG CANCER; NUDE MOUSE; SPRAGUE DAWLEY RAT; STEREOISOMERISM; SYNTHESIS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; PYRIMIDINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 77958465100     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100607r     Document Type: Article

References (17)

1. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nature Rev. Cancer 2007, 7, 169-181
2. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment N. Engl. J. Med. 2008, 358, 1160-1174
3. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075
4. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2005, 352, 786-792 (Pubitemid 40271173)
5. Lin, W. H.; Song, J. S.; Chang, T. Y.; Chang, C. Y.; Fu, Y. N.; Yeh, C. L.; Wu, S. H.; Huang, Y. W.; Fang, M. Y.; Lien, T. W.; Hsieh, H. P.; Chao, Y. S.; Huang, S. F.; Tsai, S. F.; Wang, L. M.; Hsu, J. T.; Chen, Y. R. A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors Anal. Biochem. 2008, 377, 89-94
6. Coumar, M. S.; Chu, C. Y.; Lin, C., W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T. A.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Fast-forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification. J Med. Chem. 2010, 53, 4980-4988
7. Bridges, A. J.; Cody, D. R.; Zhou, H.; McMichael, A.; Fry, D. W. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines Bioorg. Med. Chem. 1995, 3, 1651-1656
8. Showalter, H. D.; Bridges, A. J.; Zhou, H.; Sercel, A. D.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3, 2- d ]pyrimidines and pyrimido[5,4- b ]- and -[4,5- b ]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase J. Med. Chem. 1999, 42, 5464-5474
9. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res. 2004, 64, 4931-4941
10. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc. Natl. Acad. Sci. U.S.A 1998, 95, 12022-12027
11. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. (Weinheim) 2008, 341, 465-477
12. Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y. F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3- carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 2005, 48, 1107-1131
13. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res. 2004, 64, 3958-3965
14. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) J. Med. Chem. 2003, 46, 49-63
15. Yoshimura, N.; Kudoh, S.; Kimura, T.; Mitsuoka, S.; Matsuura, K.; Hirata, K.; Matsui, K.; Negoro, S.; Nakagawa, K.; Fukuoka, M. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib Lung Cancer 2006, 51, 363-368
16. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711
17. Gewald, K.; Schinke, E.; Böttcher, H. Heterocyclen aus CH-aciden Nitrilen, VIII. 2-Amino-thiophene aus methylenaktiven Nitrilen, Carbonylverbindungen und Schwefel Chem. Ber 1966, 99, 94-100